AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Aflatoxin B1 aldehyde reductase member 3

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O95154

UPID:

ARK73_HUMAN

Alternative names:

AFB1 aldehyde reductase 2

Alternative UPACC:

O95154; Q86SR4; Q8IVN6; Q8N5V6; Q8TAX1; Q9NUC3

Background:

Aflatoxin B1 aldehyde reductase member 3, also known as AFB1 aldehyde reductase 2, plays a crucial role in detoxifying aflatoxin B1 (AFB1), a potent hepatocarcinogen. This enzyme catalyzes the reduction of the dialdehyde form of AFB1 to a non-binding dialcohol, mitigating its toxic and carcinogenic effects.

Therapeutic significance:

Understanding the role of Aflatoxin B1 aldehyde reductase member 3 could open doors to potential therapeutic strategies, particularly in protecting the liver from carcinogenic substances.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.